Core Component D serves three important purposes. The first purpose of this Administrative Core is to provide all Projects and Cores with appropriate administrative and secretarial support to efficiently carry out the scientific goals of the Program Project. These essential services are not provided by the Massachusetts General Hospital. The key responsibilities of this core include: (i) general administration;(ii) fiscal oversight (budgeting, purchasing);(iii) communication and coordination of data flow;(iv) seminar series coordination and travel arrangements;and (v)preparation of manuscripts and reports. The second purpose of this core component is to closely monitor the activities of the Cox-7 Animal Colony, which is the chief facility of Core C. The Surgical and Animal Core (Core C) requires additional administrative effort for the following reasons: (i) it must adhere closely to additional regulations for breeding and maintaining animals;and (ii) it is responsible for the coordination and submission of all animal protocols. The third purpose of Core D is to provide the overall scientific direction for the Program Project. This is achieved by close interaction with: (i) the Scientific Steering Committee;(ii) External and Internal Advisory Committees;and (iii) Consultants for individual projects and cores. These groups regularly evaluate the progress and agenda of the PPG. The input of these advisory groups is discussed at the monthly Scientific Steering Committee Meetings and is incorporated in specific projects and cores.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA080124-10
Application #
8065970
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
10
Fiscal Year
2010
Total Cost
$597,831
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Khandekar, Melin J; Jain, Rakesh (2018) Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 7:S16-S20
Stylianopoulos, Triantafyllos; Munn, Lance L; Jain, Rakesh K (2018) Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends Cancer 4:258-259
Grassberger, Clemens; Hong, Theodore S; Hato, Tai et al. (2018) Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys 101:1222-1225
Zhang, Na; Chen, Jie; Ferraro, Gino B et al. (2018) Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol 299:326-333
Aoki, Shuichi; Cobbold, Mark; Zhu, Andrew X et al. (2018) Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Hepatology 67:826-828
Li, Wende; Liu, Yujiao; Yang, Weining et al. (2018) MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. J Neurooncol 136:63-71
Griveau, Amelie; Seano, Giorgio; Shelton, Samuel J et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell 33:874-889.e7
Stylianopoulos, Triantafyllos; Munn, Lance L; Jain, Rakesh K (2018) Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer 4:292-319
Incio, Joao; Ligibel, Jennifer A; McManus, Daniel T et al. (2018) Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med 10:
Sung, Yun-Chieh; Liu, Ya-Chi; Chao, Po-Han et al. (2018) Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics 8:894-905

Showing the most recent 10 out of 320 publications